Apriem Advisors Regeneron Pharmaceuticals, Inc. Transaction History

Apriem Advisors

$814 Million
Q2 2024

A detailed history of Apriem Advisors transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Apriem Advisors holds 16,333 shares of REGN stock, worth $17 Million. This represents 2.11% of its overall portfolio holdings.

Number of Shares

16,333

Previous 20,723 21.18%

Holding current value

$17 Million

Previous $19.9 Million 13.93%

% of portfolio

2.11%

Previous 2.52%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$883.2 - $1071.19 $3.88 Million - $4.7 Million	-4,390 Reduced 21.18%	16,333 $17.2 Million
Q1 2024 May 15, 2024	SELL	$902.69 - $993.35 $2.79 Million - $3.07 Million	-3,095 Reduced 12.99%	20,723 $19.9 Million
Q4 2023 Feb 14, 2024	SELL	$775.18 - $881.7 $851,922 - $968,988	-1,099 Reduced 4.41%	23,818 $20.9 Million
Q3 2023 Nov 13, 2023	SELL	$692.45 - $844.37 $474,328 - $578,393	-685 Reduced 2.68%	24,917 $20.5 Million
Q2 2023 Aug 08, 2023	SELL	$700.03 - $830.35 $353,515 - $419,326	-505 Reduced 1.93%	25,602 $18.4 Million
Q1 2023 May 12, 2023	SELL	$680.49 - $826.97 $3.58 Million - $4.35 Million	-5,265 Reduced 16.78%	26,107 $21.5 Million
Q4 2022 Feb 13, 2023	SELL	$705.89 - $766.39 $618,359 - $671,357	-876 Reduced 2.72%	31,372 $22.6 Million
Q3 2022 Nov 14, 2022	BUY	$573.97 - $724.32 $16,071 - $20,280	28 Added 0.09%	32,248 $22.2 Million
Q2 2022 Aug 08, 2022	BUY	$548.35 - $738.84 $44,964 - $60,584	82 Added 0.26%	32,220 $19 Million
Q1 2022 May 10, 2022	BUY	$595.12 - $698.43 $229,716 - $269,593	386 Added 1.22%	32,138 $22.4 Million
Q4 2021 Feb 09, 2022	BUY	$543.48 - $670.97 $17.3 Million - $21.3 Million	31,752 New	31,752 $20.1 Million

Others Institutions Holding REGN

# of Institutions

1,463

Shares Held

84.5M

Call Options Held

907K

Put Options Held

1.3M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $112B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Apriem Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Apriem Advisors with notifications on news.

Account